Head to Head Contrast: TransAct Technologies (NASDAQ:TACT) & Amarillo Biosciences (OTCMKTS:AMAR)

Amarillo Biosciences (OTCMKTS:AMAR) and TransAct Technologies (NASDAQ:TACT) are both small-cap technology companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Amarillo Biosciences and TransAct Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarillo Biosciences	0	0	0	0	0.00
TransAct Technologies	1	1	0	0	1.50

Given Amarillo Biosciences’ higher probable upside, equities analysts plainly believe Amarillo Biosciences is more favorable than TransAct Technologies.

Profitability

This table compares Amarillo Biosciences and TransAct Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarillo Biosciences	-41,453.98%	N/A	-574.29%
TransAct Technologies	-0.75%	-1.25%	-0.85%

Volatility and Risk

Amarillo Biosciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, TransAct Technologies has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Insider & Institutional Ownership

74.5% of TransAct Technologies shares are owned by institutional investors. 34.4% of Amarillo Biosciences shares are owned by company insiders. Comparatively, 19.2% of TransAct Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Amarillo Biosciences and TransAct Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A
TransAct Technologies	$51.48 million	1.02	-$1.24 million	($0.04)	-127.50

TransAct Technologies has higher revenue and earnings than Amarillo Biosciences.

Summary

TransAct Technologies beats Amarillo Biosciences on 7 of the 10 factors compared between the two stocks.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

About TransAct Technologies

TransAct Technologies Incorporated designs, develops, and markets transaction-based and specialty printers and terminals in the United States and internationally. It offers thermal printers and terminals to generate labels, coupons, and transaction records, such as receipts, tickets, and other documents. The company also provides consumable products, including POS receipt paper, inkjet cartridges, ribbons, and other printing supplies, as well as replacement parts and accessories; and maintenance and repair services. In addition, it offers EPICENTRAL print system, a software solution that enables casino operators to create promotional coupons and marketing messages, and print them at the slot machine; and technical support services, as well as spare parts and accessories. Further, the company provides BOHA! terminal that combines hardware and software components in a device that includes an operating system, touchscreen, and one or two thermal print mechanisms. It markets its products under the TransAct, BOHA!, AccuDate, Ithaca, and EPICENTRAL brands for food service technology, point of sale automation, and casino and gaming markets. The company sells its products to original equipment manufacturers, value-added resellers, and distributors, as well as directly to end-users through its Webstore transactsupplies.com. TransAct Technologies Incorporated was incorporated in 1996 and is headquartered in Hamden, Connecticut.